US Liver Imaging Reporting and Data System Version 2017: A Systematic Review and Meta-Analysis.
IF 12.1
1区 医学
Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Sunyoung Lee, Ja Kyung Yoon, Jaeseung Shin, Hyejung Shin, Anum Aslam, Aya Kamaya, Shuchi K Rodgers, Claude B Sirlin, Victoria Chernyak
求助PDF
{"title":"US Liver Imaging Reporting and Data System Version 2017: A Systematic Review and Meta-Analysis.","authors":"Sunyoung Lee, Ja Kyung Yoon, Jaeseung Shin, Hyejung Shin, Anum Aslam, Aya Kamaya, Shuchi K Rodgers, Claude B Sirlin, Victoria Chernyak","doi":"10.1148/radiol.240450","DOIUrl":null,"url":null,"abstract":"<p><p>Background The US Liver Imaging Reporting and Data System (LI-RADS) includes an assessment category (US-1, negative; US-2, subthreshold; and US-3, positive) and a visualization score reflecting image quality (VIS-A, no or minimal limitations; VIS-B, moderate limitations; and VIS-C, severe limitations). The US-3 and VIS-C impact patient treatment. Purpose To establish the distributions of categories and visualization scores, estimate the proportions of hepatocellular carcinoma (HCC) and overall malignancy in the US-3 category, and identify variables associated with the VIS-C score by conducting a meta-analysis. Materials and Methods A systematic search of articles published between January 1, 2017, and September 17, 2023, identified studies reporting distributions of US LI-RADS version 2017 categories or visualization scores. Characteristics of the study design, patient cohorts, and outcomes of interest (distributions of US categories and visualization scores, percentages of probable or definite HCC and malignancy in US-3 category, and variables associated with VIS-C) were extracted. For the meta-analysis, estimates were established with random-effects models. Results Fifteen studies comprising 39 166 US examinations were included. Of all examinations, 89.7% (95% CI: 86.8, 91.8) were categorized US-1; 4.4% (95% CI: 2.8, 6.2), US-2; and 5.9% (95% CI: 4.1, 8.0), US-3. Of the US-3 examinations, 25.9% (95% CI: 17.1, 34.7) had probable or definite HCC and 26.4% (95% CI: 18.4, 34.5) had overall malignancy. Among all examinations, 59.7% (95% CI: 46.9, 67.8) were assigned VIS-A; 32.5% (95% CI: 21.9, 41.6), VIS-B; and 7.8% (95% CI: 2.8, 14.3), VIS-C. Obesity (odds ratio [OR], 2.37; 95% CI: 1.57, 3.59), nonalcoholic fatty liver disease (NAFLD) (OR, 2.24; 95% CI: 1.64, 3.06), and Child-Pugh B or C (OR, 2.41; 95% CI: 1.43, 4.06) were associated with VIS-C score. Conclusion Overall, 90% of surveillance US results were negative (US-1), and 92% were of adequate quality (VIS-A or VIS-B); 26% of patients with US-3 results had HCC. VIS-C was associated with obesity, NAFLD, and cirrhosis. Systemic review registry no. CRD42022384925 © RSNA, 2025 <i>Supplemental material is available for this article</i>.</p>","PeriodicalId":20896,"journal":{"name":"Radiology","volume":"314 3","pages":"e240450"},"PeriodicalIF":12.1000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1148/radiol.240450","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
引用
批量引用
Abstract
Background The US Liver Imaging Reporting and Data System (LI-RADS) includes an assessment category (US-1, negative; US-2, subthreshold; and US-3, positive) and a visualization score reflecting image quality (VIS-A, no or minimal limitations; VIS-B, moderate limitations; and VIS-C, severe limitations). The US-3 and VIS-C impact patient treatment. Purpose To establish the distributions of categories and visualization scores, estimate the proportions of hepatocellular carcinoma (HCC) and overall malignancy in the US-3 category, and identify variables associated with the VIS-C score by conducting a meta-analysis. Materials and Methods A systematic search of articles published between January 1, 2017, and September 17, 2023, identified studies reporting distributions of US LI-RADS version 2017 categories or visualization scores. Characteristics of the study design, patient cohorts, and outcomes of interest (distributions of US categories and visualization scores, percentages of probable or definite HCC and malignancy in US-3 category, and variables associated with VIS-C) were extracted. For the meta-analysis, estimates were established with random-effects models. Results Fifteen studies comprising 39 166 US examinations were included. Of all examinations, 89.7% (95% CI: 86.8, 91.8) were categorized US-1; 4.4% (95% CI: 2.8, 6.2), US-2; and 5.9% (95% CI: 4.1, 8.0), US-3. Of the US-3 examinations, 25.9% (95% CI: 17.1, 34.7) had probable or definite HCC and 26.4% (95% CI: 18.4, 34.5) had overall malignancy. Among all examinations, 59.7% (95% CI: 46.9, 67.8) were assigned VIS-A; 32.5% (95% CI: 21.9, 41.6), VIS-B; and 7.8% (95% CI: 2.8, 14.3), VIS-C. Obesity (odds ratio [OR], 2.37; 95% CI: 1.57, 3.59), nonalcoholic fatty liver disease (NAFLD) (OR, 2.24; 95% CI: 1.64, 3.06), and Child-Pugh B or C (OR, 2.41; 95% CI: 1.43, 4.06) were associated with VIS-C score. Conclusion Overall, 90% of surveillance US results were negative (US-1), and 92% were of adequate quality (VIS-A or VIS-B); 26% of patients with US-3 results had HCC. VIS-C was associated with obesity, NAFLD, and cirrhosis. Systemic review registry no. CRD42022384925 © RSNA, 2025 Supplemental material is available for this article .
美国肝脏影像学报告和数据系统2017版:系统回顾和荟萃分析。
美国肝脏影像学报告和数据系统(LI-RADS)包括一个评估类别(US-1,阴性;2、阈下;US-3,积极)和反映图像质量的可视化评分(VIS-A,无限制或最小限制;VIS-B,中度限制;和VIS-C,严重限制)。US-3和VIS-C影响患者的治疗。目的建立分类和可视化评分的分布,估计US-3分类中肝细胞癌(HCC)和整体恶性肿瘤的比例,并通过meta分析确定与VIS-C评分相关的变量。对2017年1月1日至2023年9月17日期间发表的文章进行系统检索,确定了报告美国LI-RADS 2017版分类或可视化评分分布的研究。提取了研究设计的特征、患者队列和关注的结果(US分类和可视化评分的分布、US-3分类中可能或确定的HCC和恶性肿瘤的百分比,以及与VIS-C相关的变量)。对于meta分析,采用随机效应模型建立估计。结果纳入15项研究,共39166项US检查。在所有检查中,89.7% (95% CI: 86.8, 91.8)被分类为US-1;4.4% (95% ci: 2.8, 6.2), us-2;5.9% (95% CI: 4.1, 8.0), US-3。在US-3检查中,25.9% (95% CI: 17.1, 34.7)为可能或明确的HCC, 26.4% (95% CI: 18.4, 34.5)为整体恶性肿瘤。在所有检查中,59.7% (95% CI: 46.9, 67.8)被分配为VIS-A;32.5% (95% ci: 21.9, 41.6), vis-b;7.8% (95% CI: 2.8, 14.3), VIS-C。肥胖(优势比[OR], 2.37;95% CI: 1.57, 3.59),非酒精性脂肪性肝病(NAFLD) (OR, 2.24;95% CI: 1.64, 3.06), Child-Pugh B或C (or, 2.41;95% CI: 1.43, 4.06)与VIS-C评分相关。总体而言,90%的美国监测结果为阴性(US-1), 92%的结果质量良好(VIS-A或VIS-B);26%的US-3结果患者为HCC。VIS-C与肥胖、NAFLD和肝硬化相关。系统审查注册编号:CRD42022384925©RSNA, 2025本文有补充材料。
本文章由计算机程序翻译,如有差异,请以英文原文为准。